(Total Views: 561)
Posted On: 07/29/2019 1:20:41 PM
Post# of 151
$MRK News Article - Merck's KEYTRUDA (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC) https://marketwirenews.com/news-releases/merc...40520.html
(0)
(0)
My Twitter: WhyteStocks
